X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2410) 2410
Book Review (595) 595
Newsletter (127) 127
Publication (100) 100
Newspaper Article (78) 78
Magazine Article (34) 34
Book / eBook (23) 23
Conference Proceeding (23) 23
Book Chapter (15) 15
Transcript (14) 14
Trade Publication Article (3) 3
Report (2) 2
Data Set (1) 1
Reference (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (1972) 1972
humans (1888) 1888
anticonvulsants - therapeutic use (1372) 1372
epilepsy (1167) 1167
female (986) 986
anticonvulsants (959) 959
male (931) 931
clinical neurology (896) 896
epilepsy - drug therapy (853) 853
adult (745) 745
seizures (530) 530
middle aged (483) 483
anticonvulsants - adverse effects (479) 479
adolescent (474) 474
antiepileptic drugs (460) 460
anticonvulsants - economics (430) 430
child (403) 403
neurology (391) 391
psychiatry (352) 352
pharmacology & pharmacy (342) 342
drug therapy (341) 341
aged (337) 337
treatment outcome (334) 334
neurosciences (312) 312
analysis (282) 282
drugs (277) 277
animals (275) 275
carbamazepine (248) 248
epilepsy - epidemiology (246) 246
young adult (242) 242
children (241) 241
anticonvulsants - administration & dosage (232) 232
care and treatment (222) 222
epilepsy - economics (220) 220
child, preschool (215) 215
retrospective studies (196) 196
quality of life (190) 190
double-blind (189) 189
research (186) 186
risk factors (182) 182
pregnancy (173) 173
lamotrigine (172) 172
abridged index medicus (166) 166
prevalence (165) 165
epilepsy - psychology (162) 162
anticonvulsants - pharmacology (159) 159
cost-benefit analysis (158) 158
socioeconomic factors (158) 158
seizures - drug therapy (151) 151
health aspects (150) 150
medicine & public health (149) 149
behavioral sciences (147) 147
quality-of-life (143) 143
anticonvulsant (141) 141
pediatrics (140) 140
infant (132) 132
united states (130) 130
drug therapy, combination (129) 129
epilepsy - diagnosis (129) 129
medicine, general & internal (124) 124
phenytoin (124) 124
surveys and questionnaires (124) 124
comorbidity (122) 122
anticonvulsants - pharmacokinetics (121) 121
adults (119) 119
efficacy (113) 113
bipolar disorder - drug therapy (110) 110
electroencephalography (109) 109
follow-up studies (108) 108
cross-sectional studies (107) 107
prospective studies (107) 107
therapy (107) 107
antidepressants (104) 104
bipolar disorder (104) 104
studies (104) 104
cohort studies (102) 102
valproic acid (102) 102
drug costs (101) 101
refractory epilepsy (101) 101
depression (100) 100
epilepsy - therapy (100) 100
usage (100) 100
antidepressive agents - therapeutic use (97) 97
dose-response relationship, drug (97) 97
rats (97) 97
aged, 80 and over (95) 95
medical research (95) 95
valproic acid - therapeutic use (95) 95
pharmaceutical industry (94) 94
population (94) 94
topiramate (94) 94
clinical trials (92) 92
epidemiology (92) 92
time factors (89) 89
antipsychotic agents - therapeutic use (88) 88
mice (88) 88
surgery (88) 88
epilepsies, partial - drug therapy (87) 87
management (87) 87
dosage and administration (86) 86
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2598) 2598
Spanish (28) 28
French (21) 21
Russian (15) 15
German (13) 13
Swedish (9) 9
Norwegian (4) 4
Serbian (3) 3
Dutch (2) 2
Finnish (2) 2
Hungarian (2) 2
Polish (2) 2
Bosnian (1) 1
Czech (1) 1
Danish (1) 1
Japanese (1) 1
Portuguese (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Clinical Psychiatry, ISSN 0160-6689, 2012, Volume 73, Issue 11, pp. 1388 - 1394
Objective:The number of lawsuits accusing pharmaceutical companies of off-label marketing has risen in recent years. The impact of such lawsuits on drug... 
I DISORDER | MEDICAID | THERAPY | PRESCRIPTION | PSYCHIATRY | PRIOR AUTHORIZATION | LAMOTRIGINE | ANTICONVULSANTS | MEDIA | PSYCHOLOGY, CLINICAL | DISCONTINUATION | COMORBIDITY | Practice Patterns, Physicians' - economics | Medicaid - economics | United States | Drug Industry - legislation & jurisprudence | Humans | Medicare - statistics & numerical data | Medicaid - statistics & numerical data | Medicare - economics | Off-Label Use - economics | Medicaid - legislation & jurisprudence | Drug Utilization - economics | Insurance, Pharmaceutical Services - statistics & numerical data | Practice Patterns, Physicians' - statistics & numerical data | gamma-Aminobutyric Acid - economics | Anticonvulsants - adverse effects | Drug Industry - economics | Amines - therapeutic use | Amines - adverse effects | Drug Substitution - statistics & numerical data | gamma-Aminobutyric Acid - therapeutic use | Cyclohexanecarboxylic Acids - economics | Medicare - legislation & jurisprudence | Drug Utilization - statistics & numerical data | Marketing - economics | Marketing - legislation & jurisprudence | Insurance, Pharmaceutical Services - economics | gamma-Aminobutyric Acid - adverse effects | Anticonvulsants - economics | Off-Label Use - legislation & jurisprudence | Cyclohexanecarboxylic Acids - therapeutic use | Drug Approval - economics | Drug Substitution - economics | Cyclohexanecarboxylic Acids - adverse effects | Anticonvulsants - therapeutic use | Treatment Outcome | Insurance, Pharmaceutical Services - legislation & jurisprudence | Bipolar Disorder - drug therapy | Mass Media - statistics & numerical data | Drug Approval - legislation & jurisprudence | Bipolar Disorder - psychology | Drug Information Services - economics | Amines - economics | Practice Patterns, Physicians' - legislation & jurisprudence | Compensation and Redress - legislation & jurisprudence | Drug Utilization - legislation & jurisprudence | Drug Costs - legislation & jurisprudence | Index Medicus
Journal Article
Journal of Clinical Psychiatry, ISSN 0160-6689, 03/2009, Volume 70, Issue 3, pp. 378 - 386
Journal Article
Journal of Pain, ISSN 1526-5900, 2009, Volume 10, Issue 9, pp. 976 - 983
Abstract In 2004, the American Pain Society (APS) issued evidence-based fibromyalgia treatment recommendations. The objective of this claims database analysis... 
Anesthesia & Perioperative Care | Pain Medicine | medication use | Fibromyalgia | health care costs | treatment patterns | PAIN | NEUROSCIENCES | CLINICAL NEUROLOGY | Drug Costs | Fibromyalgia - therapy | Analgesics, Opioid - economics | Practice Patterns, Physicians' - economics | Rheumatology - statistics & numerical data | Humans | Middle Aged | Cost of Illness | Chiropractic - utilization | Male | Health Services - utilization | Drug Utilization - economics | Health Care Costs - trends | Office Visits - utilization | Prescription Drugs | Female | Benzodiazepines - economics | Chiropractic - economics | Anticonvulsants - economics | Insurance Coverage - economics | Health Benefit Plans, Employee - economics | Anticonvulsants - therapeutic use | Health Resources - economics | Analgesics, Opioid - therapeutic use | Patient Acceptance of Health Care - statistics & numerical data | Physicians, Family - economics | Antidepressive Agents - therapeutic use | Fibromyalgia - diagnosis | Health Care Costs - statistics & numerical data | Office Visits - economics | Rheumatology - economics | Antidepressive Agents - economics | Fibromyalgia - economics | Physicians, Family - statistics & numerical data | Benzodiazepines - therapeutic use | Mental Health - statistics & numerical data | Cohort Studies | Care and treatment | Utilization | Pain | Gabapentin | Medical care | Serotonin uptake inhibitors | Health aspects | Benzodiazepines | Medical care, Cost of | Index Medicus
Journal Article
Journal Article
The European Journal of Health Economics, ISSN 1618-7598, 2/2010, Volume 11, Issue 1, pp. 35 - 44
The objective of the present study was to describe a new model of the cost-effectiveness of treatment of generalized anxiety disorder (GAD) and its application... 
Health care costs | Cost estimation models | Cost estimates | Utilities costs | Anxiety disorders | Minimization of cost | Drug design | Drug therapy | Modeling | Cost efficiency | I19 | Economic Policy | Generalized anxiety disorder | Models economics | Public Finance & Economics | Venlafaxine | Public Health/Gesundheitswesen | Pregabalin | Cost-effectiveness | Economics / Management Science | STATES | EFFICACY | MODEL | SIMULATION | CARE | TRIAL | DOUBLE-BLIND | PAROXETINE | HEALTH POLICY & SERVICES | ECONOMICS | EPILEPSY | Confidence Intervals | Humans | Cyclohexanols - economics | Models, Economic | Antidepressive Agents, Second-Generation - therapeutic use | Antidepressive Agents, Second-Generation - economics | gamma-Aminobutyric Acid - economics | Psychiatric Status Rating Scales | gamma-Aminobutyric Acid - therapeutic use | Anxiety Disorders - drug therapy | Anticonvulsants - economics | Quality-Adjusted Life Years | Economics, Pharmaceutical | Anxiety Disorders - economics | Anticonvulsants - therapeutic use | Psychometrics | Treatment Outcome | Models, Statistical | Spain | Venlafaxine Hydrochloride | Cost-Benefit Analysis | Cyclohexanols - therapeutic use | gamma-Aminobutyric Acid - analogs & derivatives | Delayed-Action Preparations | Monte Carlo Method | Analysis | Medical care, Cost of | Studies | Economic models | Prescription drugs | Health care expenditures | Health economics | Mental disorders | Economic theory | Anxieties | Index Medicus | Original Paper
Journal Article
Journal Article
Value in Health, ISSN 1098-3015, 2013, Volume 16, Issue 2, pp. 334 - 344
Abstract Objective To assess the cost-effectiveness of duloxetine in the treatment of chronic low back pain (CLBP) from a US private payer perspective. Methods... 
Internal Medicine | chronic low back pain | cost-effectiveness | duloxetine | cost-utility analysis | pharmacoeconomic model | ACUTE-RENAL-FAILURE | WOMAC INDEX SCORES | RANDOMIZED CONTROLLED-TRIAL | THERAPEUTIC ARTHRITIS RESEARCH | PROTON-PUMP INHIBITORS | COMMUNITY-BASED POPULATION | NONSTEROIDAL ANTIINFLAMMATORY DRUGS | HEALTH CARE SCIENCES & SERVICES | DIABETIC PERIPHERAL NEUROPATHY | HEALTH POLICY & SERVICES | ECONOMICS | PLACEBO-CONTROLLED TRIAL | MARK-3 UTILITY SCORES | Analgesics, Opioid - economics | Thiophenes - therapeutic use | Markov Chains | Meta-Analysis as Topic | United States | Humans | Models, Economic | Analgesics, Opioid - adverse effects | Anticonvulsants - adverse effects | Thiophenes - economics | Anticonvulsants - economics | Quality-Adjusted Life Years | Economics, Pharmaceutical | Anti-Inflammatory Agents, Non-Steroidal - economics | Serotonin Uptake Inhibitors - therapeutic use | Anticonvulsants - therapeutic use | Serotonin Uptake Inhibitors - adverse effects | Analgesics, Opioid - therapeutic use | Serotonin Uptake Inhibitors - economics | Low Back Pain - economics | Low Back Pain - drug therapy | Anti-Inflammatory Agents, Non-Steroidal - adverse effects | Anti-Inflammatory Agents, Non-Steroidal - therapeutic use | Cost-Benefit Analysis | Duloxetine Hydrochloride | Chronic Disease | Insurance, Health - economics | Index Medicus
Journal Article
Journal Article
Health Policy and Planning, ISSN 0268-1080, 05/2016, Volume 31, Issue 4, pp. 504 - 513
Introduction There is an immense need for scaling-up neuropsychiatric care in low-income countries. Contextualized cost-effectiveness analyses (CEAs) provide... 
neuropsychiatric disorders | ethics | Cost-effectiveness | mental health | MIDDLE-INCOME COUNTRIES | BUTAJIRA | EFFICACY | SUB-SAHARAN AFRICA | BIPOLAR I DISORDER | SCHIZOPHRENIA | STOCHASTIC LEAGUE TABLES | RELAPSE PREVENTION | HEALTH CARE SCIENCES & SERVICES | HEALTH POLICY & SERVICES | GLOBAL MENTAL-HEALTH | EPILEPSY | Anticonvulsants - economics | Schizophrenia - therapy | Humans | Mental Health Services - economics | Capacity Building - economics | Anticonvulsants - therapeutic use | Capacity Building - organization & administration | Bipolar Disorder - economics | Epilepsy - economics | Health Care Costs | Mental Health Services - organization & administration | Cost-Benefit Analysis | Depression - economics | Epilepsy - drug therapy | Bipolar Disorder - therapy | Schizophrenia - economics | Depression - therapy | Epilepsy - therapy | Ethiopia | Intervention | Mental disorders | Epilepsy | Disorders | Cost reduction | Schizophrenia | Values | Bipolar disorder | Epidemiology | Information systems | Literature reviews | Prices | Mental health care | Cost effectiveness | Health costs | Neuropsychology | Salaries | Low income people | Public health policy | Effectiveness | First generation | Health care policy | Bipolar affective disorder | Depression | Efficacy | Coverage | Health care services policy | Studies | Services | Interventions | Reviews | Disability adjusted life years | Treatment programs | Scaling | Cost analysis | Antiepileptic drugs | Low income countries | Psychiatry | Health administration | Original
Journal Article